Drugs / Benznidazole
Benznidazole
also known as
BZN · Abarax · BNZ · [14C]-Benznidazole · Abarax (Benznidazole 100mg or 50mg). · Benznidazol · Benznidazole (N-benzil-2-nitro-1-imidazolacetamida) · Benznidazolum · +6 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BENZNIDAZOLE | — | 2017-08-29 | fda.gov ↗ |
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05523596 | Aug 2023 → Oct 2025 | — | IC-MedTech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03739541 | Jul → Sep 2018 | — | Exeltis France | Completed | No outcome recorded |
| Phase 1 | NCT03892213 | Oct → Dec 2014 | Chagas disease | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03981523 | Dec 2019 → May 2024 | Chagas disease | University of Texas, El Paso | Completed | No outcome recorded |
| Phase 2 | NCT03191162 | Apr 2017 → Sep 2020 | Chagas disease | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03378661 | Nov 2016 → Jan 2018 | Chagas disease | Drugs for Neglected Diseases | Unknown | No outcome recorded |
| Phase 2 | NCT01377480 | Jul 2011 → Jul 2014 | Chagas disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06339710 | Jan 2025 → Jan 2026 | Chagas disease | Evandro Chagas Institute of Clinical Research | Withdrawn | No outcome recorded |
| Phase 3 | NCT04897516 | Jul 2021 → Jun 2026 overdue | Chagas disease | Laboratorio Elea Phoenix S.A. | Recruiting | No outcome recorded |
| Phase 3 | NCT04024163 | Sep 2019 → Aug 2027 expected | Chagas disease | Insud Pharma | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03672487 | Jun 2019 → May 2024 | Chagas disease | Tulane University School of Public Health and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00123916 | Nov 2004 → Jul 2015 | Chagas disease, heart disorder | Population Health Research Institute | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01755403 | Dec 2012 → Nov 2013 | Chagas disease | Barcelona Centre for International Health Research | Completed | No outcome recorded |
| Phase 4 | NCT01549236 | May 2011 → Aug 2012 | Chagas disease | Drugs for Neglected Diseases | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00699387 | Apr 2007 → May 2011 | Chagas disease | Hospital de Niños R. Gutierrez de Buenos Aires | Completed | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06632600 Comparator | Apr 2025 → Mar 2027 expected | Chagas disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT01489228 Comparator | Jun 2011 → Aug 2012 | Chagas disease | Drugs for Neglected Diseases | Unknown | No outcome recorded |
| Phase 2 | NCT01162967 Comparator | Sep 2010 → Dec 2012 | Chagas disease | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02369978 Comparator | Aug 2015 → Aug 2018 | Chagas disease | Universidad Autónoma de Bucaramanga | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02386358 Comparator | Mar 1999 → Dec 2012 | Chagas disease | Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01678599 Background | Apr 2011 → Dec 2012 | Chagas disease | Drugs for Neglected Diseases | Completed | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benznidazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02369978 ↗ |
| Known as | [14C]-Benznidazole | “A Phase I, Open-label, Study of the Absorption, Metabolism and Excretion, of [14C]-Benznidazole (BNZ) Following a Single Oral Dose in Healthy Male Subjects” NCT03739541 ↗ |
| Known as | Abarax | “This study was a prospective, open-label, single-center clinical trial approved by the local ethics committee. Patients received BNZ at 2.5 mg/kg of body weight/12 h (Abarax,...” PMID 25824212 ↗ Mar 20151“Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.” NCT04897516 ↗ |
| Known as | Abarax (Benznidazole 100mg or 50mg). | “Abarax® (Benznidazole 100mg or 50mg).” NCT03892213 ↗ |
| Known as | Benznidazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Known as | Benznidazole (N-benzil-2-nitro-1-imidazolacetamida) | “Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)” NCT01489228 ↗ |
| Known as | Benznidazolum | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Known as | Benzonidazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Known as | BNZ | “Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice.” PMID 32293523 ↗ Apr 20201“benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose)” NCT01377480 ↗ |
| Known as | BZN | “Either benznidazole (BZN) or nifurtimox (NFX) is recommended as equivalent to treat Trypanosoma cruzi infection.” PMID 31307503 ↗ Jul 20193“Current treatments are limited to two nitroheterocyclic compounds: nifurtimox and benznidazole (BZN).” PMID 41027700 ↗ Sep 2025 “Benznidazole (BZN) is the drug of choice for preconceptional treatment to reduce parasitic load.” PMID 32831069 ↗ Aug 2020 “Current approved specific treatments for CD include nifurtimox (NFX) and benznidazole (BZN)” NCT03981523 ↗ |
| Known as | NSC-299972 | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Known as | RADANIL | “benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days” NCT00699387 ↗ |
| Known as | RO 07-1051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Known as | RO-7-1051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Known as | Rochagan | ChEMBL registry synonym — accepted as the source's own label CHEMBL110 ↗ |
| Modality | Small molecule | “Benznidazole, a nitroimidazole derivative, has been recommended for the treatment of acute and congenital Trypanosoma cruzi infection (Chagas' disease).” PMID 8937280 ↗ Nov 1996 |
| Route | Oral | “Daily po Benznidazole” NCT00123916 ↗ |